Skip to main content
PGEN
NASDAQ Life Sciences

Precigen's PAPZIMEOS Generates $3.4M Q4 Revenue, Gains J-Code, Targets Cash Flow Break-Even

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.9
Mkt Cap
$1.097B
52W Low
$1.11
52W High
$5.465
52W Position info
161% above low
Off High info
47% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

PGEN has more than doubled off its 52-week low of $1.11.

Summary

Precigen reported full year 2025 financial results, highlighting $3.4 million in net product revenue for PAPZIMEOS in the fourth quarter of 2025, its first partial quarter of commercial sales. The company announced strong commercial momentum for PAPZIMEOS, including a significant increase in demand in Q1 2026 and the assignment of a permanent J-code (J3404) effective April 1, 2026, which will streamline reimbursement and patient access. With $100.4 million in cash, cash equivalents, and investments as of December 31, 2025, Precigen expects to fund operations to cash flow break-even. These updates confirm the company's successful transition to a commercial-stage entity with a clear path to financial sustainability, making this a material positive development for traders.

At the time of this announcement, PGEN was trading at $2.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $1.11 to $5.47. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

PGEN - Latest Insights

PGEN
Nov 04, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.99
Real-time Price: $4.47 info
Change: -$0.5173 (-10%) info
Market Cap: $1.6B info
PGEN
Nov 04, 2026, 4:05 PM EST
Source: PR Newswire
Importance Score:
8
Price at Filing: $5.01
Real-time Price: $4.47 info
Change: -$0.5413 (-11%) info
Market Cap: $1.6B info
PGEN
Sep 21, 2026, 7:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $7.93
Real-time Price: $4.47 info
Change: -$3.46 (-44%) info
Market Cap: $1.6B info
PGEN
Aug 04, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $7.27
Real-time Price: $4.47 info
Change: -$2.80 (-39%) info
Market Cap: $1.6B info
PGEN
Aug 04, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.35
Real-time Price: $4.47 info
Change: -$2.88 (-39%) info
Market Cap: $1.6B info